SCHEMBL10312205

SCHEMBL10312205

C/C=C/c1cc(Nc2nc(/C=C/c3cccc(F)c3)nc(NCc3ccncc3)n2)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH3 Q9ULD8 2/20 0.40
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.38
PAK4 O96013 3/20 0.37
PLK4 O00444 2/20 0.37
CHEK1 O14757 1/20 0.37
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37
CCNA2 P20248 1/20 0.37
CCND1 P24385 1/20 0.37
CDK2 P24941 1/20 0.37
CCND3 P30281 1/20 0.37
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
SLC2A1 P11166 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FLT3 P36888 3/20 0.35
NTRK1 P04629 6/20 0.35
GRK6 P43250 1/20 0.34
JAK3 P52333 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312198 0.90 IGF1R (0.42) MAPTMAPK1PAK4PLK4LMNA
SCHEMBL10312165 0.89 NPSR1 (0.42) KCNH3MAPTMAPK1PAK4PLK4
SCHEMBL10312195 0.89 PAK4 (0.48) KCNH3MAPTMAPK1PAK4PLK4
SCHEMBL10312133 0.89 NTRK1 (0.39) KCNH3CHEK1SLC2A1NTRK1JAK3
SCHEMBL10312211 0.84 IGF1R (0.50) PAK4PLK4NTRK1BTKJAK2
SCHEMBL10312203 0.81 FLT3 (0.38) PAK4PLK4CHEK1CDK1CDK4
SCHEMBL10312103 0.81 HRH4 (0.47) MAPTPAK4PLK4CHEK1CDK1
SCHEMBL10312153 0.80 PKM (0.40) MAPTPAK4PLK4LMNAPOLB
SCHEMBL10312129 0.79 KDM4E (0.41) MAPK1LMNASLC2A1SMN1; SMN2IGF1R
SCHEMBL10312189 0.79 PAK4 (0.51) PAK4PLK4FLT3NTRK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 KCNH3 2257/4885MAPT 1313/4885MAPK1 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.